- Home
- HCWB vs PMAX Comparison
HCWB vs PMAX Comparison
Compare HCWB & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- PMAX
- Stock Information
- Founded
- HCWB 2018
- PMAX 2019
- Country
- HCWB United States
- PMAX Hong Kong
- Employees
- HCWB N/A
- PMAX N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- PMAX
- Sector
- HCWB Health Care
- PMAX
- Exchange
- HCWB Nasdaq
- PMAX Nasdaq
- Market Cap
- HCWB 10.8M
- PMAX 7.9M
- IPO Year
- HCWB 2021
- PMAX 2024
- Fundamental
- Price
- HCWB $4.30
- PMAX $0.38
- Analyst Decision
- HCWB Strong Buy
- PMAX
- Analyst Count
- HCWB 1
- PMAX 0
- Target Price
- HCWB $35.00
- PMAX N/A
- AVG Volume (30 Days)
- HCWB 116.1K
- PMAX 1.6M
- Earning Date
- HCWB 08-13-2025
- PMAX 04-28-2025
- Dividend Yield
- HCWB N/A
- PMAX N/A
- EPS Growth
- HCWB N/A
- PMAX N/A
- EPS
- HCWB N/A
- PMAX N/A
- Revenue
- HCWB $1,445,145.00
- PMAX $4,694,079.00
- Revenue This Year
- HCWB $178.36
- PMAX N/A
- Revenue Next Year
- HCWB N/A
- PMAX N/A
- P/E Ratio
- HCWB N/A
- PMAX N/A
- Revenue Growth
- HCWB N/A
- PMAX N/A
- 52 Week Low
- HCWB $3.55
- PMAX $0.28
- 52 Week High
- HCWB $100.80
- PMAX $4.70
- Technical
- Relative Strength Index (RSI)
- HCWB 42.79
- PMAX N/A
- Support Level
- HCWB $4.02
- PMAX N/A
- Resistance Level
- HCWB $4.44
- PMAX N/A
- Average True Range (ATR)
- HCWB 0.31
- PMAX 0.00
- MACD
- HCWB 0.08
- PMAX 0.00
- Stochastic Oscillator
- HCWB 31.85
- PMAX 0.00
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.